Fortamet Generic

Jump to

Lupin Q4 profit seen up 33% to Rs 726cr, US biz may drive growth

Analysts feel exclusivity on Glumetza generic & full quarter of price hikes on Fortamet generic may drive US numbers.
Lupin hopeful of getting Fortamet case through

Lupin had launched Fortamet, a diabetic drug, at risk in the US, causing an injunction against the drug. Chief Financial Officer S Ramesh clarified that Fortamet generic was launched only for few days.
Lupin launches Fortamet Generic in US; stock down

Lupin has launched Fortamet Generic at risk in the US, reports CNBC-TV18. It touched an intraday high of Rs 466 and an intraday low of Rs 454.90. At 15:14 hrs the share was quoting at Rs 454.90, down Rs 8.65, or 1.87%.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Fortamet Generic

Lupin Q4 profit seen up 33% to Rs 726cr, US biz may drive growth

Lupin hopeful of getting Fortamet case through

Lupin launches Fortamet Generic in US; stock down